Recon: FDA approves Luye’s long-acting schizophrenia drug Rykindo; EU proposes changes to pharma law to avoid shortages
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy